Literature DB >> 10882650

Superantigens and cystic fibrosis: resistance of presenting cells to dexamethasone.

J Ben-Ari1, D Gozal, R J Dorio, C M Bowman, A Reiff, S M Walker.   

Abstract

Staphylococcus aureus, a common pulmonary pathogen in cystic fibrosis (CF), produces exotoxins that are extremely potent superantigens. A number of animal studies have shown that superantigens cause pulmonary inflammation, but the possible role of superantigens in CF has not been investigated. The present study assessed possible differences between control and CF B cells in presenting superantigens to T cells. Immortalized B-cell lines were used as superantigen-presenting cells to avoid environmental influences (e.g., infection or antibiotics) common to freshly isolated cells. The results show that CF B-cell lines presented a staphylococcal superantigen to the immortalized T-cell line (Jurkat) as effectively as did control B-cell lines as measured by interleukin-2 production. However, in contrast to the case for control B-cell lines, dexamethasone did not inhibit CF B-cell lines from presenting superantigen. The resistance of superantigen-presenting CF B cells to corticosteroids suggests that the pulmonary response to superantigens may be poorly regulated in CF, leading to an exaggerated inflammatory response to S. aureus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882650      PMCID: PMC95912          DOI: 10.1128/CDLI.7.4.553-556.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  35 in total

1.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.

Authors:  A Ray; K S LaForge; P B Sehgal
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

Review 2.  Superantigens: mechanism of T-cell stimulation and role in immune responses.

Authors:  A Herman; J W Kappler; P Marrack; A M Pullen
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  Risks of alternate-day prednisone in patients with cystic fibrosis.

Authors:  B J Rosenstein; H Eigen
Journal:  Pediatrics       Date:  1991-02       Impact factor: 7.124

Review 4.  An intricate route to immortality.

Authors:  B Sugden
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

Review 5.  Pathogenesis of the pseudomonas lung lesion in cystic fibrosis.

Authors:  R B Fick
Journal:  Chest       Date:  1989-07       Impact factor: 9.410

6.  Protein kinase c-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6).

Authors:  E Kontny; M Ziółkowska; A Ryzewska; W Maśliński
Journal:  Cytokine       Date:  1999-11       Impact factor: 3.861

7.  Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro.

Authors:  O Tabary; J M Zahm; J Hinnrasky; J P Couetil; P Cornillet; M Guenounou; D Gaillard; E Puchelle; J Jacquot
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

8.  Induction of tumor necrosis factor alpha and interleukin-8 gene expression in bronchial epithelial cells by toxic shock syndrome toxin 1.

Authors:  V Aubert; D Schneeberger; A Sauty; J Winter; P Sperisen; J D Aubert; F Spertini
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

9.  Ligand-receptor interactions required for commitment to the activation of the interleukin 2 gene.

Authors:  A Weiss; R Shields; M Newton; B Manger; J Imboden
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

10.  Cystic fibrosis patients' B-lymphocyte response is resistant to the in vitro enhancing effect of corticosteroids.

Authors:  D Emilie; M C Crevon; R Chicheportiche; M T Auffredou; R Barot-Ciorbaru; G Lenoir; J M Dayer; P Galanaud
Journal:  Eur J Clin Invest       Date:  1990-12       Impact factor: 4.686

View more
  5 in total

Review 1.  Staphylococcus aureus superantigens and airway disease.

Authors:  Claus Bachert; Philippe Gevaert; Paul van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

2.  Treatment with rhDNase in patients with cystic fibrosis alters in-vitro CHIT-1 activity of isolated leucocytes.

Authors:  M Weckmann; C Schultheiss; A Hollaender; I Bobis; J Rupp; M V Kopp
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

3.  The reciprocal interplay between TNFα and the circadian clock impacts on cell proliferation and migration in Hodgkin lymphoma cells.

Authors:  Mónica Abreu; Alireza Basti; Nikolai Genov; Gianluigi Mazzoccoli; Angela Relógio
Journal:  Sci Rep       Date:  2018-07-31       Impact factor: 4.379

Review 4.  Superantigens and nasal polyps.

Authors:  Claus Bachert; Thibaut van Zele; Philippe Gevaert; Lore De Schrijver; Paul Van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2003-11       Impact factor: 4.919

Review 5.  Immunomodulation in Cystic Fibrosis: Why and How?

Authors:  Vincent D Giacalone; Brian S Dobosh; Amit Gaggar; Rabindra Tirouvanziam; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.